Natco Drug Discovery Private Limited, a active private limited company, was established on 02 May 1989 in Hyderabad, Telangana, India. Engaging in drug formulation & development within the professional, scientific and technical sector, it holds CIN: U24230TG1989PTC009942. Registered under ROC Roc Hyderabad. it is unlisted. It has an authorized capital of ₹0.50 M and a paid-up capital of ₹0.10 M.
Formerly known as Natchem Pharma Pvt Ltd.. It upholds a compliant status. Its leadership includes Sadasiva Rao Nannapaneni (Director), Pathuri Srinivasa Rao (Director). Past directors included Sadasiva Rao Nannapaneni, Satish Kumar Gaddipati. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at Natco House,Road No.2 Banjarahills, Hyderabad, Telangana, 500033.
U24230TG1989PTC009942
009942
02 May 1989
₹0.50 M
₹0.10 M
Roc Hyderabad
Unlisted
Active
Explore comprehensive insights into Natco Drug Discovery Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sadasiva Rao Nannapaneni | Director | 01 Jul 2016 | Current |
| Pathuri Srinivasa Rao | Director | 19 Jun 2002 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Additional Director | 30 Sep 2016 | Past |
| Pramod Abcsdd | Director | 01 Jul 2016 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Natco Drug Discovery Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 99913.72% decrease in profit. The company's net worth observed a substantial decline by a decrease of 99913.73%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Natco Drug Discovery had a public holding of 50.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
There are no open charges registered against the company as per our records.
Unlock and access historical data on people associated with Natco Drug Discovery, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Natco Drug Discovery, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Natco Drug Discovery's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on Natco Drug Discovery Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was documented.
Natco Drug Discovery Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Hyderabad. was recorded as a recent event.
Progress on Sadasiva Rao Nannapaneni was appointed as a Director was appointed as a Director on 01 Jul 2016 & has been associated with this company since 9 years 5 months . was documented.
Pathuri Srinivasa Rao was appointed as a Director was appointed as a Director on 19 Jun 2002 & has been associated with this company since 23 years 5 months . was recorded as a recent event.
Natco Drug Discovery Private Limited was registered on 02 May 1989 with Roc Hyderabad & aged 36 years 7 months as per MCA records. was recorded as a recent event.
The Delhi High Court has prohibited Natco Pharma from producing and selling the cancer drug Olaparib, marketed as 'BRACANAT' or under any other name, until further notice. The court's decision came in response to a lawsuit by Kudos Pharmaceuticals, which claimed that Natco was infringing on its patent for Olaparib. The court found Natco's challenge to the patent's validity unconvincing, leading to the injunction. Natco had sought to revoke Kudos' patent only after the lawsuit was filed, despite no previous opposition to it..
Hyderabad: Natco Pharma has announced that the operations at the Company's factory located at Manali Industrial Area, Chennai, Tamil Nadu have been temporarily disrupted due to cyclone with ... .
Natco Pharma Q2 FY24 results: Revenue increased by 138.69% YoY & profit increased by 549.65% YoY.
Hygiene and wellness brand Pee Safe has raised $3 million in a Series B funding round led by Natco Pharma Limited and Rainmatter Health. The funds will be used to expand the company's retail presence in India, expand overseas, and allocate additional resources to marketing and awareness initiatives. Pee Safe offers a range of personal hygiene products, including reusable pads, tampons, and menstrual cups, and aims to address the lack of access to safe menstrual and personal hygiene products for Indian women..
The CIN of Natco Drug Discovery Private Limited is U24230TG1989PTC009942.
Natco Drug Discovery Private Limited is headquartered at Natco House,Road No.2 Banjarahills, Hyderabad, Telangana, 500033.
Natco Drug Discovery Private Limited was incorporated on 02 May 1989.
The current directors of Natco Drug Discovery Private Limited are
The primary industry of Natco Drug Discovery Private Limited is Professional, Scientific And Technical.
Natco Drug Discovery Private Limited is unlisted.
The authorized capital of Natco Drug Discovery Private Limited is ₹0.50 M, and the paid-up capital is ₹0.10 M.
The compliance status of Natco Drug Discovery Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX